BJDX

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on developing automated, rapid, cost-effective diagnostic systems for near-patient testing in hospital and clinical settings. Headquartered in Acton, Massachusetts, Bluejay is developing the Symphony IL-6 test system, designed to measure interleukin-6 (IL-6), a biomarker associated with severe inflammation and sepsis. The company's technology aims to provide fast, accurate IL-6 measurements at the point of care, enabling physicians to make timely treatment decisions for critically ill patients. Interleukin-6 is an inflammatory cytokine that becomes elevated during severe infections, sepsis, and other critical inflammatory conditions. Rapid, accurate measurement of IL-6 levels can help clinicians identify patients at risk for sepsis, assess disease severity, guide treatment decisions, and monitor response to therapy. Currently, IL-6 testing typically requires sending samples to central laboratories with turnaround times of hours or days, limiting clinical utility in acute care settings where rapid results are essential. Bluejay's Symphony system is designed to deliver results in approximately 10 minutes from small blood samples at or near the patient bedside. The company's Symphony platform combines immunoassay technology with automated sample processing and analysis in a compact, easy-to-use system suitable for hospital emergency departments, intensive care units, and other acute care settings. Bluejay is conducting clinical studies to validate the Symphony IL-6 test's performance and demonstrate clinical utility. The company must secure FDA clearance or approval, establish reimbursement, build manufacturing and commercialization capabilities, and demonstrate clinical and economic value to drive hospital adoption. The sepsis diagnostics market represents a significant opportunity given the high prevalence, mortality, and healthcare costs associated with sepsis. Bluejay competes with both existing laboratory-based tests and other point-of-care diagnostic developers while working to establish IL-6 testing as a standard component of sepsis management.